Developer docs
API playgroundTry for free, no card

Search company profiles

M33 Growth

Full company profile

uuid0000dwv

Namestring
M33 Growth
Legal namestring
M33 Growth LLC
Websiteurl
m33growth.com
Company typeenum
Private
Founded yearint
2018
Descriptiontext

M33 Growth is a Boston-based venture and growth-stage investment firm that partners with bootstrapped entrepreneurs in North American B2B software and healthcare services to accelerate growth through concentrated capital and hands-on operating support. Founded in 2017-2018 by Mike Anello and Gabe Ling (with Brian Shortsleeve), the firm invests $10-40 million per company and takes meaningful ownership positions, offering both primary capital for growth and secondary capital for shareholder liquidity. M33 deliberately limits its active-lead portfolio to approximately 19 companies — its next investment will be company #19 — under the "Mach 33 / Escape Velocity" branding, asserting that concentration produces deeper engagement than diversified growth funds.

The firm's operating model rests on four core competency pillars — Go-To-Market execution, Strategy, M&A advisory, and Talent — delivered through an in-house team supplemented by named Growth Acceleration Specialists (covering Product/AI, Engineering/AI, Data-centric AI, Marketing, and Post Sale) and a 12-person advisor ecosystem. In recent years M33 has added a proprietary "AI Execution" framework aimed at helping portfolio companies re-imagine products, optimize pricing, and deploy AI-powered sales execution, positioning the firm as an early mover in AI-enabled value creation for B2B software. The portfolio spans vertical software and tech-enabled services (Apogee Interactive, BeSmartee, BFC Software, Clear Demand, GoDocs, Leading2Lean, O3 Solutions, Operix, PerformLine, Rosnet, SmartKargo, Swift Comply, Thanx, Total Synergy, YAPI), healthcare services (Luke, Pediatrica Health Group, U.S. Neurology Associates, The Oncology Institute of Hope & Innovation — the latter taken public on NASDAQ as TOI), and infrastructure/EPC software (ARES PRISM, Titan Cloud, W Energy). M33 Growth closed a $260 million second fund in February 2020.

The business model is classic closed-end growth equity: management fees on committed/invested capital and carried interest on realized exits. Revenue is not publicly disclosed; the firm is privately held as M33 Growth LLC. Sourcing is direct and referral-driven — outbound to bootstrapped founders, inbound via the "Strike Zone" criteria page and C-Suite Resource Center content marketing, plus referrals from the advisor network and prior founders. Co-investment relationships with Charlesbank Capital Partners, True Wind Capital, Roca Partners, Havencrest, Ribbit Capital, and RHI Group indicate a developed syndication network that supplements Fund II's $260M of primary capital.

Short descriptiontext

M33 Growth is a Boston-based growth equity firm founded in 2017-2018 that invests $10-40 million per company in bootstrapped North American B2B software and healthcare services businesses, providing capital plus hands-on operating support across GTM, Strategy, M&A, Talent, and AI Execution across a concentrated portfolio of approximately 19 companies.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersBoston, United States
HQ citystring
Boston
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
growth equity investing, venture capital partnerships, private equity management, portfolio company support, bootstrap company funding
Industry2 codes
PRIMARYFSANACAA
Technology & Software Growth Equity
SECONDARYFSANACAB
Healthcare & Life Sciences Growth Equity
NAICS code2 codes
  • Portfolio Management and Investment Advice52394
  • Other Investment Pools and Funds5259
SIC code1 code
  • Investment Advice6282
Product category
Growth Equity / Venture Capital
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Investment Management
TypeManaged Services
Description

M33 Growth generates returns through equity investments in bootstrapped B2B software and healthcare companies. Their revenue comes from management fees and carried interest on fund returns. They invest $10-40M per company and provide both primary capital for growth and secondary capital for shareholder liquidity.

m33growth.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure
Pricing details1 tier
1$10-40M investment per company with meaningful ownership
ModelOtherBilling cadenceMulti-year contract
Notes

Investment range of $10-40 million per portfolio company. Provides both primary capital for growth and secondary capital for shareholder liquidity.

m33growth.com
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

M33 Growth is a venture and growth stage investment firm that partners with bootstrapped entrepreneurs in B2B software and healthcare by providing both primary growth capital ($10–40M per company) and secondary capital for shareholder liquidity. Beyond capital, the firm delivers hands-on operational support across four core areas — Go-To-Market execution, Strategy, M&A, and Talent — augmented by a proprietary AI Execution capability for portfolio companies.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

M33 Growth is a growth equity firm that provides capital and operational resources to bootstrapped B2B software and healthcare companies. Rather than offering a traditional SaaS product, the firm provides investment services alongside four core operational capabilities: Go-To-Market execution, Strategy, M&A advisory, and Talent acquisition. The firm also offers AI Execution advisory services to help portfolio companies integrate AI capabilities into their products and operations.

Product and service7 records
1B2B Software Growth Equity
CategoryGrowth Equity Investment
Description

Growth equity investment program targeting bootstrapped or minimally capitalized B2B software companies with $5M+ ARR, 20%+ organic growth, and 90%+ gross retention. M33 deploys $10–40M per company and takes a meaningful ownership stake.

2Healthcare Services Growth Equity
CategoryGrowth Equity Investment
Description

Growth equity investment program for bootstrapped U.S. healthcare services companies with $15M+ revenue or $2M+ EBITDA that demonstrate better patient outcomes at lower cost through patient-first clinical models.

3Secondary Capital for Shareholder Liquidity
CategoryInvestment Structure
Description

Secondary capital structure within M33 Growth's investments that allows founders and existing shareholders to partially monetize their stakes while retaining meaningful upside in the company.

4GTM Execution Support
CategoryOperational Advisory
Description

Hands-on go-to-market execution support delivered to portfolio companies by M33 Growth's team and growth acceleration specialists, covering sales leadership, demand generation, and pricing.

5M&A Advisory and Execution
CategoryOperational Advisory
Description

Strategic M&A advisory and execution support for portfolio companies, including acquisition sourcing, deal execution, and integration guidance, delivered by M33 Growth's Platforms & Strategic M&A leadership.

6Talent Acquisition and Development
CategoryOperational Advisory
Description

Talent acquisition and executive development support for portfolio companies, led by M33 Growth's Head of Talent and supported by an ecosystem of operating advisors.

7AI Execution Advisory
Scale indicator3 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Kansas City-based growth equity firm investing $10–$50M in profitable, founder-led B2B software companies. Closely matched check size and bootstrapped-software thesis to M33.

TypeDirect peer
Description

Growth equity firm focused exclusively on bootstrapped, founder-led B2B software companies. Highly comparable thesis around capital-efficient SaaS investing with operational value-add.

TypeDirect peer
Description

Boston-based growth equity firm investing in bootstrapped, profitable B2B software and tech-enabled services companies with $5M–$50M of revenue. Most direct comparable given shared geography, founder-friendly positioning, and concentrated portfolio approach.

TypeDirect peer
Description

Growth equity arm of Susquehanna International Group, investing in bootstrapped and capital-efficient B2B software and services. Comparable ticket sizes and founder-friendly positioning.

TypeDirect peer
Description

Growth equity firm focused on bootstrapped, profitable B2B software and technology-enabled services companies. Similar investment criteria around ARR thresholds and gross retention.

TypeBroad incumbent
Description

Boston-headquartered growth equity firm investing across technology, healthcare, and growth-stage companies. Overlap with M33 in B2B software and healthcare but operates at much larger AUM and check sizes.

TypeBroad incumbent
Description

Boston-based growth equity firm with substantial software and healthcare investing practice. Broader incumbent competitor for B2B SaaS and healthcare services deals, but operates at meaningfully larger fund size.

TypeBroad incumbent
Description

Large growth-stage investor in B2B software with strong value-add operating model and AI focus. Comparable in operating-partner approach but at vastly greater AUM and stage range.

TypeRegional player
Description

Boston-based private equity firm investing in healthcare and technology-enabled services. Overlap with M33's healthcare thesis and Boston footprint, though typically at smaller scale and different stage.

TypeDirect peer
Description

Growth-oriented PE firm investing in founder-led businesses with $5M–$50M EBITDA across B2B services and software. Comparable thesis around partnership-oriented, non-extractive capital.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers18 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles13 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment18 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

M33 Growth

Growth Equity / Venture Capitalm33growth.com

M33 Growth is a Boston-based growth equity firm founded in 2017-2018 that invests $10-40 million per company in bootstrapped North American B2B software and healthcare services businesses, providing capital plus hands-on operating support across GTM, Strategy, M&A, Talent, and AI Execution across a concentrated portfolio of approximately 19 companies.

What M33 Growth does

M33 Growth is a Boston-based venture and growth-stage investment firm that partners with bootstrapped entrepreneurs in North American B2B software and healthcare services to accelerate growth through concentrated capital and hands-on operating support. Founded in 2017-2018 by Mike Anello and Gabe Ling (with Brian Shortsleeve), the firm invests $10-40 million per company and takes meaningful ownership positions, offering both primary capital for growth and secondary capital for shareholder liquidity. M33 deliberately limits its active-lead portfolio to approximately 19 companies — its next investment will be company #19 — under the "Mach 33 / Escape Velocity" branding, asserting that concentration produces deeper engagement than diversified growth funds.

The firm's operating model rests on four core competency pillars — Go-To-Market execution, Strategy, M&A advisory, and Talent — delivered through an in-house team supplemented by named Growth Acceleration Specialists (covering Product/AI, Engineering/AI, Data-centric AI, Marketing, and Post Sale) and a 12-person advisor ecosystem. In recent years M33 has added a proprietary "AI Execution" framework aimed at helping portfolio companies re-imagine products, optimize pricing, and deploy AI-powered sales execution, positioning the firm as an early mover in AI-enabled value creation for B2B software. The portfolio spans vertical software and tech-enabled services (Apogee Interactive, BeSmartee, BFC Software, Clear Demand, GoDocs, Leading2Lean, O3 Solutions, Operix, PerformLine, Rosnet, SmartKargo, Swift Comply, Thanx, Total Synergy, YAPI), healthcare services (Luke, Pediatrica Health Group, U.S. Neurology Associates, The Oncology Institute of Hope & Innovation — the latter taken public on NASDAQ as TOI), and infrastructure/EPC software (ARES PRISM, Titan Cloud, W Energy). M33 Growth closed a $260 million second fund in February 2020.

The business model is classic closed-end growth equity: management fees on committed/invested capital and carried interest on realized exits. Revenue is not publicly disclosed; the firm is privately held as M33 Growth LLC. Sourcing is direct and referral-driven — outbound to bootstrapped founders, inbound via the "Strike Zone" criteria page and C-Suite Resource Center content marketing, plus referrals from the advisor network and prior founders. Co-investment relationships with Charlesbank Capital Partners, True Wind Capital, Roca Partners, Havencrest, Ribbit Capital, and RHI Group indicate a developed syndication network that supplements Fund II's $260M of primary capital.

M33 Growth firmographics

Firmographics
Name
M33 Growth
Legal name
M33 Growth LLC
Website
https://m33growth.com
Company type
Private
Founded year
2018
Operating status
Operating
Headcount range
11–50 employees
Short description
M33 Growth is a Boston-based growth equity firm founded in 2017-2018 that invests $10-40 million per company in bootstrapped North American B2B software and healthcare services businesses, providing capital plus hands-on operating support across GTM, Strategy, M&A, Talent, and AI Execution across a concentrated portfolio of approximately 19 companies.
Ownership category
akta.pro rank

M33 Growth industry classification

Industry
Product category
Growth Equity / Venture Capital
NAICS
Portfolio Management and Investment Advice (52394), Other Investment Pools and Funds (5259)
SIC
Investment Advice (6282)
akta.pro industry
PRIMARYFSANACAA
Technology & Software Growth Equity
SECONDARYFSANACAB
Healthcare & Life Sciences Growth Equity

Keywords

  • Growth equity investing
  • Venture capital partnerships
  • Private equity management
  • Portfolio company support
  • Bootstrap company funding

Where M33 Growth is headquartered

Location

Headquarters

HQ city
Boston
HQ country
United States
HQ region
North America

Offices1 record

Markets served

M33 Growth business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

  1. Investment Management: M33 Growth generates returns through equity investments in bootstrapped B2B software and healthcare companies. Their revenue comes from management fees and carried interest on fund returns. They invest $10-40M per company and provide both primary capital for growth and secondary capital for shareholder liquidity.

Pricing tiers

ModelBillingPrice
OtherMulti-year contract$10-40M investment per company with meaningful ownership

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

M33 Growth product offering

Product offering

Core offering

M33 Growth is a venture and growth stage investment firm that partners with bootstrapped entrepreneurs in B2B software and healthcare by providing both primary growth capital ($10–40M per company) and secondary capital for shareholder liquidity. Beyond capital, the firm delivers hands-on operational support across four core areas — Go-To-Market execution, Strategy, M&A, and Talent — augmented by a proprietary AI Execution capability for portfolio companies.

Product overview

M33 Growth is a growth equity firm that provides capital and operational resources to bootstrapped B2B software and healthcare companies. Rather than offering a traditional SaaS product, the firm provides investment services alongside four core operational capabilities: Go-To-Market execution, Strategy, M&A advisory, and Talent acquisition. The firm also offers AI Execution advisory services to help portfolio companies integrate AI capabilities into their products and operations.

Differentiator

Problem solved

Functional benefit

Products and services

  • B2B Software Growth Equity Growth equity investment program targeting bootstrapped or minimally capitalized B2B software companies with $5M+ ARR, 20%+ organic growth, and 90%+ gross retention. M33 deploys $10–40M per company and takes a meaningful ownership stake.
  • Healthcare Services Growth Equity Growth equity investment program for bootstrapped U.S. healthcare services companies with $15M+ revenue or $2M+ EBITDA that demonstrate better patient outcomes at lower cost through patient-first clinical models.
  • Secondary Capital for Shareholder Liquidity Secondary capital structure within M33 Growth's investments that allows founders and existing shareholders to partially monetize their stakes while retaining meaningful upside in the company.
  • GTM Execution Support Hands-on go-to-market execution support delivered to portfolio companies by M33 Growth's team and growth acceleration specialists, covering sales leadership, demand generation, and pricing.
  • M&A Advisory and Execution Strategic M&A advisory and execution support for portfolio companies, including acquisition sourcing, deal execution, and integration guidance, delivered by M33 Growth's Platforms & Strategic M&A leadership.
  • Talent Acquisition and Development Talent acquisition and executive development support for portfolio companies, led by M33 Growth's Head of Talent and supported by an ecosystem of operating advisors.
  • AI Execution Advisory

Companies that use M33 Growth

Customer profile

Named customers18 records

Segments3 records

Ideal customer profiles3 records

M33 Growth technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

M33 Growth partnerships and signals

Strategic signal

Scale indicators3 records

Recent moves6 records

Expansion highlights6 records

M33 Growth competitors and assessment

Company assessment

Direct peers

  • Five Elms Capital: Kansas City-based growth equity firm investing $10–$50M in profitable, founder-led B2B software companies. Closely matched check size and bootstrapped-software thesis to M33.
  • Mainsail Partners: Growth equity firm focused exclusively on bootstrapped, founder-led B2B software companies. Highly comparable thesis around capital-efficient SaaS investing with operational value-add.
  • Volition Capital: Boston-based growth equity firm investing in bootstrapped, profitable B2B software and tech-enabled services companies with $5M–$50M of revenue. Most direct comparable given shared geography, founder-friendly positioning, and concentrated portfolio approach.
  • Susquehanna Growth Equity: Growth equity arm of Susquehanna International Group, investing in bootstrapped and capital-efficient B2B software and services. Comparable ticket sizes and founder-friendly positioning.
  • Peak Equity Partners: Growth equity firm focused on bootstrapped, profitable B2B software and technology-enabled services companies. Similar investment criteria around ARR thresholds and gross retention.
  • Trivest Partners: Growth-oriented PE firm investing in founder-led businesses with $5M–$50M EBITDA across B2B services and software. Comparable thesis around partnership-oriented, non-extractive capital.

Broad incumbents

  • Summit Partners: Boston-headquartered growth equity firm investing across technology, healthcare, and growth-stage companies. Overlap with M33 in B2B software and healthcare but operates at much larger AUM and check sizes.
  • TA Associates: Boston-based growth equity firm with substantial software and healthcare investing practice. Broader incumbent competitor for B2B SaaS and healthcare services deals, but operates at meaningfully larger fund size.
  • Insight Partners: Large growth-stage investor in B2B software with strong value-add operating model and AI focus. Comparable in operating-partner approach but at vastly greater AUM and stage range.

Regional players

  • Riverside Partners: Boston-based private equity firm investing in healthcare and technology-enabled services. Overlap with M33's healthcare thesis and Boston footprint, though typically at smaller scale and different stage.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

M33 Growth financial estimates

Financial estimate

Revenue estimate

Valuation estimate

M33 Growth leadership team

Management profile

Number of profiles

Profiles13 records

M33 Growth funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M33 Growth M&A and investment

M&A and investment

M&A

Investments18 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about M33 Growth

What does M33 Growth do?

M33 Growth is a venture and growth stage investment firm that partners with bootstrapped entrepreneurs in B2B software and healthcare by providing both primary growth capital ($10–40M per company) and secondary capital for shareholder liquidity. Beyond capital, the firm delivers hands-on operational support across four core areas — Go-To-Market execution, Strategy, M&A, and Talent — augmented by a proprietary AI Execution capability for portfolio companies.

Is M33 Growth a public or private company?

M33 Growth is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was M33 Growth founded?

M33 Growth was founded in 2018. It employs 11 to 50 people.

Where is M33 Growth based?

M33 Growth is headquartered in Boston, United States, in the North America region.

How does M33 Growth make money?

One revenue line is on record: investment Management.

Who are M33 Growth's main competitors?

Direct peers on record are Five Elms Capital, Mainsail Partners, Volition Capital, Susquehanna Growth Equity, Peak Equity Partners and Trivest Partners. Broad incumbents are Summit Partners, TA Associates and Insight Partners. Riverside Partners is listed as a regional player.

Does M33 Growth have an API?

No public API is recorded for M33 Growth.

What industry is M33 Growth in?

M33 Growth's product category is Growth Equity / Venture Capital. Its primary akta.pro industry code is FSANACAA, Technology & Software Growth Equity, with a secondary code of FSANACAB, Healthcare & Life Sciences Growth Equity. Its NAICS code is 52394 and its SIC code is 6282.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Startup ResearcherCarma Secures Strategic Investment from M33 GrowthCarma, a Denver-based digital infrastructure software provider, secured a strategic investment from M33 Growth. Ryan Kubacki, former CEO of Contruent, joins as CEO, while co-founders remain involved. The company plans to accelerate its product roadmap and expand engineering and go-to-market teams.Business Wire BlogCarma Accelerates Its Innovative AI-Fueled Network and Digital Infrastructure Platform with Strategic Investment from M33 GrowthCarma, a network and digital infrastructure platform, secured a strategic investment from M33 Growth to accelerate its product roadmap and expand teams. The investment will support growth, and Ryan Kubacki will join as CEO, while co-founders Frank and Joe McDermott remain involved.Venture Capital Access OnlinePediatrica Health Group Raises $28 Million Series B to Expand Equitable Access to Pediatric Primary CarePediatrica Health Group closed a $28 million Series B led by Valspring Capital, with M33 Growth participating. The funding will support organic growth, strategic acquisitions, and expansion of its pediatric primary care model across Florida and Texas.GlobeNewswireU.S. Neurology Associates Partners with M33 Growth to Transform Neurological CareM33 Growth announced a partnership with U.S. Neurology Associates, a physician services organization, to transform neurological care. Nitin Jain will serve as CEO, and the partnership aims to provide comprehensive care including in-office infusions and diagnostics. USNA seeks to offer cost-effective, integrated care aligned with value-based care models.EIN PresswireContruent Software Announces Successful New Investment Following Transformative SaaS Growth Under M33 Growth OwnershipContruent Software, a lifecycle cost management platform for capital programs, announced a successful new investment from The Riverside Company, completing a four-year partnership with M33 Growth during which it transformed from a legacy on-premises business to a cloud-native SaaS leader. Since M33 Growth's 2021 investment, the company nearly quadrupled in size, built a customer base of 200+ organizations managing over $85 billion in annual construction spend, and expanded operations across three continents. The new ownership group intends to accelerate product innovation and international expansion as demand for capital program visibility and efficiency continues to grow globally.PR NewswireRosnet Secures Strategic Investment from M33 Growth to Accelerate Innovation and Market LeadershipRosnet, a restaurant operations software provider, secured a strategic investment from M33 Growth to accelerate product innovation and market leadership. The investment aims to enhance its back-of-house platform for multi-unit operators, with partners including Applebee's, Wendy's, and IHOP. Rosnet's CEO said the partnership will expand market presence and support.EIN PresswireTotal Synergy Acquires Factor AE and Secures Significant Growth Investment to Help Accelerate A&E Market LeadershipTotal Synergy acquired Factor AE, a practice management platform for A&E firms, and secured investment from PSG and M33 Growth. The funding will drive AI innovation, product development, and go-to-market acceleration. The move aims to expand Total Synergy's North American presence and set a new standard for A&E practice management.The CurrencySwiftComply makes its first two acquisitions after M33 Capital investment - The CurrencySwiftComply has acquired stormwater compliance software providers CloudCompli and NPDESPro following a $40 million valuation backing from M33 Capital. The acquisitions are intended to unify regulatory compliance programs for water utilities across North America by integrating these services into SwiftComply's platform.PediatricaPediatrica Health Group Partners with M33 Growth to Bring Groundbreaking Changes to Pediatric Primary CareM33 Growth has partnered with Roberto L. Palenzuela to establish Pediatrica Health Group, aiming to transform pediatric primary care through modern technologies. This initiative intends to improve access to health resources for children and support for healthcare providers amid a reported 51% burnout rate among primary care providers. The partnership seeks to create a collaborative care model that positively impacts pediatric health.